Login to Your Account

Financings NEWS

LONDON – Pediatric medicines specialist Advicenne SA closed a €16 million round, providing the means to complete phase III development of ADV7103 for treating renal tubulopathy.

With multiple phase II studies of lead compound, mipsagargin, under its belt, Inspyr Therapeutics Inc. inked an agreement with private equity firm Milost Global Inc. for up to $100 million to fund the next stage of development.

LONDON – Cell Medica Ltd. has raised £60 million (US$74.1 million) in a series C round to fund the parallel development of four second-generation T-cell cancer immunotherapy programs targeted at solid tumors.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: